Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Paul Emery

Paul Emery is Arthritis Research UK Professor of Rheumatology and Director, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Director, Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust.

Recent stories

  • Biosimilar infliximab is now available for the management of a number of rheumatology conditions and, in the next few years, additional biosimilar medicines will become available for rheumatology patients. In the image, x-ray of arthritic feet

    Biosimilar medicines in rheumatologySubscription

    11 NOV 2015

    The long-term safety of biosimilar medicines is unknown, but while their use in rheumatology practice is supported, switching patients currently responding and tolerating the reference product is not.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.